GB9316580D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB9316580D0
GB9316580D0 GB939316580A GB9316580A GB9316580D0 GB 9316580 D0 GB9316580 D0 GB 9316580D0 GB 939316580 A GB939316580 A GB 939316580A GB 9316580 A GB9316580 A GB 9316580A GB 9316580 D0 GB9316580 D0 GB 9316580D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939316580A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB939316580A priority Critical patent/GB9316580D0/en
Publication of GB9316580D0 publication Critical patent/GB9316580D0/en
Priority to JP7506202A priority patent/JPH09501421A/en
Priority to CA002169159A priority patent/CA2169159C/en
Priority to PCT/EP1994/002515 priority patent/WO1995004528A2/en
Priority to CN94193729A priority patent/CN1112180C/en
Priority to EP94926129A priority patent/EP0720476A1/en
Priority to AU76099/94A priority patent/AU688789B2/en
Priority to ZA945930A priority patent/ZA945930B/en
Priority to TW083107332A priority patent/TW354256B/en
Priority to US08/827,625 priority patent/US5866162A/en
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
GB939316580A 1993-08-10 1993-08-10 Pharmaceutical composition Pending GB9316580D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB939316580A GB9316580D0 (en) 1993-08-10 1993-08-10 Pharmaceutical composition
AU76099/94A AU688789B2 (en) 1993-08-10 1994-07-29 Pharmaceutical composition containing a drug/beta -cyclodextrin complex in combination with an acid-base couple
CN94193729A CN1112180C (en) 1993-08-10 1994-07-29 Pharmaceutical composition containing drug/beta-cyclodextrin complex in combination with acid-base couple
CA002169159A CA2169159C (en) 1993-08-10 1994-07-29 Pharmaceutical composition containing a drug/.beta.-cyclodextrin complex in combination with an acid-base couple
PCT/EP1994/002515 WO1995004528A2 (en) 1993-08-10 1994-07-29 PHARMACEUTICAL COMPOSITION CONTAINING A DRUG/β-CYCLODEXTRIN COMPLEX IN COMBINATION WITH AN ACID-BASE COUPLE
JP7506202A JPH09501421A (en) 1993-08-10 1994-07-29 Pharmaceutical composition containing a drug / β-cyclodextrin complex in combination with an acid-base couple
EP94926129A EP0720476A1 (en) 1993-08-10 1994-07-29 PHARMACEUTICAL COMPOSITION CONTAINING A DRUG/$g(b)-CYCLODEXTRIN COMPLEX IN COMBINATION WITH AN ACID-BASE COUPLE
ZA945930A ZA945930B (en) 1993-08-10 1994-08-08 Pharmaceutical composition
TW083107332A TW354256B (en) 1993-08-10 1994-08-11 A pharmaceutical composition for oral consumption in aqueous solution comprising a drug/<beta>-cyclodextrin complex and a pharmaceutically acceptable acid-base couple
US08/827,625 US5866162A (en) 1993-08-10 1997-04-09 Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939316580A GB9316580D0 (en) 1993-08-10 1993-08-10 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB9316580D0 true GB9316580D0 (en) 1993-09-29

Family

ID=10740244

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939316580A Pending GB9316580D0 (en) 1993-08-10 1993-08-10 Pharmaceutical composition

Country Status (9)

Country Link
EP (1) EP0720476A1 (en)
JP (1) JPH09501421A (en)
CN (1) CN1112180C (en)
AU (1) AU688789B2 (en)
CA (1) CA2169159C (en)
GB (1) GB9316580D0 (en)
TW (1) TW354256B (en)
WO (1) WO1995004528A2 (en)
ZA (1) ZA945930B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
ES2171110B1 (en) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas PHARMACEUTICAL COMPOSITION BASED ON IBUPROFEN AND PROCEDURE FOR PREPARATION.
ES2189682B1 (en) * 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. DRINKABLE PREPARATION UNDERSTANDING KETOPROPHEN AND ITS EMPLOYMENT IN THE PROCESSING OF PROCESSES PROCESSING WITH FEVER, INFLAMMATION AND / OR PAIN, IN AN ANIMAL COLLECTIVE, SIMULTANEOUSLY.
CZ2004262A3 (en) * 2004-02-20 2005-06-15 I. Q. A., A. S. Stable, taste-acceptable syrups containing ibuprofen and process of their preparation
CN101404990B (en) 2006-03-16 2012-04-25 诺瓦提斯公司 Solid dosage form containing a taste masked active agent
KR20160033796A (en) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 Formulations of low dose diclofenac and beta-cyclodextrin
TW201038296A (en) * 2009-04-27 2010-11-01 Aplicaciones Farmacodinamicas S A Lab De Ibuprofen lysinate oral suspension
DK2253329T3 (en) * 2009-04-27 2017-01-16 Laboratorio De Aplicaciones Farm S A Oral ibuprofen lysinate suspension.
JP5853430B2 (en) * 2010-06-21 2016-02-09 大正製薬株式会社 Oral solution
CN101987089B (en) * 2010-11-10 2012-07-04 天大药业(珠海)有限公司 Effervescent medicinal preparation
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
CA2877724A1 (en) * 2012-06-28 2014-01-03 Der-Yang Lee Racecadotril liquid compositions
BR112015005968A2 (en) * 2012-09-18 2017-07-04 Mcneil Ppc Inc sustained release oral dosage forms comprising particles of low melting propionic acid
CN111116794A (en) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 Preparation method of neutral polymeric material for papermaking

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920230A (en) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
DE3440288A1 (en) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien PHARMACEUTICAL PREPARATION WITH A CONTENT OF AT LEAST ONE Mucous-irritating SUBSTANCE OR THE LIKE, PARTICULARLY PROFESSIONALS, AND METHOD FOR THE PRODUCTION THEREOF
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
CH677606A5 (en) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
DE3838431A1 (en) * 1988-11-12 1990-05-17 Bayer Ag IBUPROFEN SHOWER PREPARATIONS
IT1227626B (en) * 1988-11-28 1991-04-23 Vectorpharma Int SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION
US5019663A (en) * 1989-04-03 1991-05-28 Mobil Oil Corp. Heat balanced paraffin upgrading with co-fed oxygenate
JPH02279631A (en) * 1989-04-18 1990-11-15 Yamanouchi Pharmaceut Co Ltd Cyclodextrin clathrate for medicine and its production
CA2009326C (en) * 1989-05-09 1998-01-27 Lawrence J. Daher Aqueous granulation solution and a method of tablet granulation
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4027927A1 (en) * 1990-09-04 1992-03-05 Bayer Ag SHOWER COMPONENT AND METHOD FOR THEIR PRODUCTION
DE4038314A1 (en) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm COMPLEXES OF THE ACTIVE ENANTIOMER OF THE IBUPROFEN WITH CYCLODEXTRIN
JP2579251B2 (en) * 1991-03-12 1997-02-05 ロシェ・コンシューマー・ヘルス・(ワールドワイド)・リミテッド Non-effervescent ibuprofen composition

Also Published As

Publication number Publication date
ZA945930B (en) 1995-04-05
CA2169159C (en) 2005-01-25
EP0720476A1 (en) 1996-07-10
CN1112180C (en) 2003-06-25
WO1995004528A3 (en) 1995-03-16
AU688789B2 (en) 1998-03-19
WO1995004528A2 (en) 1995-02-16
TW354256B (en) 1999-03-11
CA2169159A1 (en) 1995-02-16
CN1133006A (en) 1996-10-09
AU7609994A (en) 1995-02-28
JPH09501421A (en) 1997-02-10

Similar Documents

Publication Publication Date Title
HU9402974D0 (en) Pharmaceutical composition
GB9317686D0 (en) Pharmaceutical compositions
GB9317610D0 (en) Pharmaceutical compositions
GB9316580D0 (en) Pharmaceutical composition
GB2272375B (en) Pharmaceutical composition
PL314036A1 (en) Pharmaceutical composition
CA2100836A1 (en) Pharmaceutical Composition
GB9317504D0 (en) Pharmaceutical compositions
ZA945752B (en) Pharmaceutical composition
GB9221707D0 (en) Pharmaceutical composition
GB9318880D0 (en) Pharmaceutical composition
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9420129D0 (en) Pharmaceutical compositions
GB9308849D0 (en) Pharmaceutical composition
GB9417021D0 (en) Pharmaceutical composition
GB9321671D0 (en) Pharmaceutical composition
GB9320688D0 (en) Pharmaceutical composition
HU9303386D0 (en) Pharmaceutical composition
GB9314709D0 (en) Pharmaceutical composition
GB9314564D0 (en) Pharmaceutical composition
ZA947913B (en) Pharmaceutical composition
HU9303511D0 (en) Pharmaceutical composition
GB9318350D0 (en) Pharmaceutical composition
ZA935269B (en) Pharmaceutical composition
GB9306582D0 (en) Pharmaceutical compositions